BLAINJECTIONINJECTABLEPriority Review
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
LEMTRADA (alemtuzumab) by Sanofi is cd52-directed antibody interactions [moa]. First approved in 2001.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEMTRADA (alemtuzumab) is a CD52-directed monoclonal antibody that depletes lymphocytes through cytolytic mechanisms. It is primarily used in multiple sclerosis and has been approved since 2001. The drug works by binding to CD52 antigen on the surface of T and B lymphocytes, leading to their elimination.
$0.909MPart D
LOE ApproachingProduct is approaching loss of exclusivity with minimal Part D spending and claims, indicating a mature, declining revenue base that may constrain team expansion.
Mechanism of Action
CD52-directed Antibody Interactions
Pharmacologic Class:
CD52-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Started Jul 2022
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Started Jul 2022
50 enrolled
Chronic Granulomatous Disease
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
Started Dec 2021
0Multiple Sclerosis
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
Started Aug 2021
1 enrolled
Relapsing-Remitting Multiple Sclerosis
Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab
Started Mar 2021
70 enrolled
Multiple Sclerosis
Worked on LEMTRADA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.